PubMed Health⌕ Search

Biomedical subjects

L S Yu

Publications and source records attributed to L S Yu.

31 records · Page 2Linked to original sources
PubMed1989

In vitro comparison of velocity profiles and turbulent shear distal to polyurethane trileaflet and pericardial prosthetic valves.

A comparative study of flow dynamics past biomer trileaflet valves and a pericardial bioprosthetic valve under steady and physiological pulsatile flow conditions in vitro is reported in this paper. The velocity profiles and the turbulent shear stresses distal to the valves were measured using laser Doppler anemometry. The authors' results showed that the velocity profiles distal to the trileaflet valves were similar to that measured distal to the pericardial valve. Higher magnitudes of absolute turbulent shear stresses were measured distal to the synthetic valves in comparison to the pericardial valves. However, when the stresses were nondimensionalized with respect to the orifice diameter at the inlet aspect, the stresses were comparable for all of the three valves. With design modifications to increase the orifice diameter at the inlet aspect of the polyurethane valves, the turbulent stresses distal to the valves can be minimized. Such in vitro studies on the flow dynamics past the polyurethane valves can provide information towards design changes to improve the performance characteristics of these valves. Polyurethane valves with flow characteristics comparable to the pericardial valves can be manufactured relatively inexpensively compared to mechanical or tissue valve prosthesis. Hence, the synthetic valves may be a viable alternative for short-term use in total artificial heart devices as a bridge to transplant.

Bioprosthesis↗
PubMed1988

Development of smaller artificial ventricles and valves made by vacuum forming.

Implantable prosthetic ventricles and trileaflet valves made by vacuum forming have been developed and implant tested. All components are made from Pellethane. Recognizing the need for smaller as well as larger ventricles, designs with effective stroke volumes of 50, 85, 100 and 130 cc have been tested with several valve types. The pneumatically driven Utah ventricular assist device (UVAD) can be used as a total artificial heart (TAH) or ventricular assist device (VAD) by using the appropriate inflow and outflow adapters. In vitro durability testing has demonstrated ventricular lifetime beyond two years and valve lifetime to nearly one and one half years. The polymer valves have lower regurgitation than mechanical valves. Animal implantation experience includes 21 TAH implants and 16 left ventricular assist device (LVAD) implantations. TAH survival ranges from 2 to 210 days. LVAD animals have lived up to 116 days before elective termination. The animal were healthy and grew normally. The devices exhibit a "Starling's Law" response. One TAH animal survived 72 days before successful explantation followed by transplantation. At autopsy, this animal had no renal infarcts. Hematology data has demonstrated the existance of little or no intravascular hemolysis (PF Hb less than 5 mg%). The "Philadelphia" version of the UVAD vacuum formed ventricles are small enough to be implanted without thrombus provoking connectors. Eight animals have received this TAH and survived up to 120 days. Vacuum forming offers a rapid and inexpensive way to produce reliable and effective total artificial hearts and valves for widespread, temporary clinical application in any size adult human.

Animals↗
PubMedDate not supplied

Hemodynamic comparisons of polyurethane trileaflet and bioprosthetic heart valves.

Hemodynamic comparison of two polyurethane prosthetic heart valves with a bioprosthetic valve is presented. The valves were incorporated in a pulse duplicator simulating physiologic pulsatile flow, and comparisons between the valves were made on the transvalvular pressure drop, percent regurgitation, valve orifice area, rate of opening and closing as well as the performance index. The results showed that the functional characteristics of the polyurethane valve compared favorably with that of the bioprosthetic valve. The polyurethane valve can be a viable and inexpensive alternative, especially for short-term use in a total artificial heart as a bridge to transplant.

Bioprosthesis↗
PubMedDate not supplied

New polyurethane valves in new soft artificial hearts.

This article describes new bistable valves, and introduces a new soft heart that is easy to implant. Earlier, five polyurethane (PU) valves were implanted in the mitral position in sheep. All five survived for 1 year or more, and the valves, although calcified, were intact. Since the opening resistance was somewhat high, valves that are bistable were developed, which means they may be open or closed. These valves have lower opening resistance, and regurgitation is similar to that of mechanical valves. Eight calves have been implanted with a new, soft total artificial heart (TAH). Seven had bistable leaflet valves; the eighth had mechanical (Bicer) valves in the inflow position. Four of the calves were sacrificed after 22 to 43 days. At autopsy, the number of thromboemboli found, particularly in the kidneys, was low compared with previous experiments. None of these animals received anticoagulants other than the heparin given during heart/lung bypass.

Animals↗
PubMedDate not supplied

Chronic in vivo evaluation of an electrohydraulic total artificial heart.

Development of the Abiomed total artificial heart (TAH) designed for human use is progressing. Implant durations of longer than 60 days have been achieved in calves. The device consists of blood pumps, valves, and a hydraulic atrial flow balancing chamber fabricated from polyetherurethane. The energy converter, a centrifugal hydraulic pump with a rotary fluid switching valve, is positioned between the blood pumps. In two consecutive chronic in vivo studies (47 days and longer than 60 days), cardiac output was maintained in excess of 8 l/min. The atrial flow balancing chamber maintained a mean right-to-left pressure gradient of 7.5 and -1.4 mmHg in each respective study. There were no pulmonary complications. Platelet counts, fibrinogen concentrations, and hematocrit values returned to baseline levels within 20 days, whereas bilirubin, serum glutamic-oxaloacetic transaminase, blood urea nitrogen, and creatinine levels returned to normal within 1 week of implant. After the first post-operative day, plasma free hemoglobin levels of less than 10 mg/dl indicated no device-related hemolysis throughout the duration of the studies. At explant (47 day study), pathologic analysis showed no renal infarcts, no tissue necrosis, and no thermal damage. The device was fully encapsulated by 2-4 mm thick fibrous connective tissue. A newly designed textured-to-smooth surface inflow showed no signs of pannus ingrowth or thrombotic complications. These studies demonstrate that this TAH is suitable for long-term implantation.

Animals↗
PubMedDate not supplied

Progress in the development of the ABIOMED total artificial heart.

The ABIOMED implantable total artificial hearts in the final phase of engineering development. The system has a compact electrohydraulically driven energy converter sandwiched between two blood pumps, an internal electronics pack, an internal battery, a transcutaneous energy transmission coil for power transmission, and external wearable electronics pack and battery. The current effort is to complete development of the system during 1996 in preparation for formal pre clinical testing of the device. In vivo studies with the current thoracic unit (ABH II) have achieved 108 days of survival verifying the thermal, physiologic, and hematologic compatibility of the system. The abdominal implantable electronics pack showed no thermal dissipation problem. System improvements include scaling down the size of the thoracic unit, and efficiency enhancement in the power and hybrid electronics. The new system (ABH III) retains the flow capacity of greater than 10 L/min. Size reduction results in an atrial to sternal dimension that would fit 98% and 75% of men and women, respectively.

Animals↗
PubMedDate not supplied

Evaluation of a stented polyurethane mitral valve prosthesis.

In the search for the perfect valve prosthesis, polyurethane has been used for its excellent physical properties, but thrombosis and embolism have been real problems. The authors investigated the performance and durability of a 23 mm vacuum formed polyurethane Tricuspid Semilunar Valve, in the mitral position. The valve was implanted in eight sheep using standard cardiopulmonary bypass and intermittent aortic cross clamping. Two early failures were due to valve tears. After modification of the manufacturing process, six further valves were implanted in six sheep. All were anticoagulated with warfarin. The valves were calcified on echocardiography and had increasing transvalvular gradients beginning 3 months postoperatively. All six survived and were killed 1-2.5 years after implantation. Despite gross calcification of the leaflets, medium-term function was good. Careful serial sections of brain showed no evidence of thromboembolism. Both kidneys contained small calcium emboli, but no evidence of infarction. Despite calcification, with good medium-term function and no cerebral emboli, this valve may find application in temporary cardiac assist devices.

Animals↗
PubMedDate not supplied

Soft artificial ventricles for infants and adults, with or without a clamshell.

The quick connect system and mechanical disk valves used in total artificial hearts (TAH) are sources of thrombogenesis and blood damage. Our soft TAH, which has no quick connectors, can be squeezed and bent, making it easily implantable, and blood damage is reduced by the use of trileaflet and biflap polyurethane valves. The soft ventricles were made by vacuum forming, after which the pieces were welded together by radiofrequency heat sealing. A rapid clamshell can be pushed and slipped over the soft heart to prevent deformation of the ventricle. Three calves have had the 60 cc soft TAH implanted, both with and without a clamshell. The cardiac outputs were as high as 7 L/min, without a vacuum applied during diastole. Two lambs received the 20 cc TAH (as an acute experiment); it fit and functioned well. One healthy lamb received a 20 cc left ventricular assist device (LVAD) with a pulsating artificial atrium as a survival experiment. The lamb survived for 8 days, after which the device was removed and the lamb returned to the meadow. Thrombosis in the TAH was minimal, and the plasma free hemoglobin values in all the TAH and LVAD experiments were usually lower than 5 mg/dl and often lower than 2 mg/dl.

Adult↗
PubMedDate not supplied

In vitro ultrasound characterization of a polyurethane trileaflet valve.

Polyurethane synthetic trileaflet valves were compared with commercial prostheses in vitro, in a pulse duplicator using ultrasound to characterize the flow velocities and patterns. Flow-pressure drop behavior was in the middle range of other prosthetic valves. Diastolic regurgitant jets were located by color Doppler ultrasound, and there appeared to be some leakage through the leaflet fold at the commissure. Nevertheless, the closing volumes and closed valve leakage volumes were, on average, lower than other prosthetic valves. Systolic 20 Hz spectral oscillations detected with pulsed Doppler and continuous wave Doppler were attributed to leaflet flutter in the open valve.

Aortic Valve↗
PubMedDate not supplied

An atrial hydraulic shunt in a total artificial heart. A balance mechanism for the bronchial shunt.

An implantable TAH must be able to maintain physiologic atrial pressures over a range of left side shunt flows, which in humans can range up to 5% of the total cardiac output (CO). The authors describe the characteristics of an atrial hydraulic shunt in an electrohydraulic TAH. A small (10 cc stroke) chamber placed in line between the left atrial cuff and the inflow valve is shunted to the right hydraulic chamber. High left atrial pressure increases the volume displaced by this chamber; this concurrently reduces the right chamber stroke volume and flow relative to the left side. For left atrial pressures (LAP) between 0 and 15 mmHg, CO increased from approximately 3 to > 9 L/min (Starling-like behavior). This was attainable with bronchial flow settings between 0.2 to 0.7 L/min, satisfying physiologic needs. Left atrial pressure and RAP (right atrial pressure) tracked each other. The mean difference, LAP-RAP, remained within 5 mmHg at low filling pressures and approached 0 mmHg difference at high filling pressures. The results showed that the atrial hydraulic shunt method can adequately compensate for and manage physiologic left-right flow differences.

Animals↗
PubMedDate not supplied

A compact and noise free electrohydraulic total artificial heart.

The ABIOMED total artificial heart (TAH) is designed for long-term tether-free use in patients with end-stage heart disease. Blood pumping is achieved through hydraulic fluid motion across flexing diaphragms. The hydraulic power is derived from a miniature centrifugal pump (50% efficiency). Flow directional change needed for alternate left and right filling and ejection is achieved with a rotary valve. With no mechanical contact with the flexing membrane, the wedge angle between the two pumps sandwiching the energy convertor can be easily optimized for anatomic fit. The blood pumps (80 ml strokes) are fitted with trileaflet polyetherurethane valves (24 mm). The TAH is implanted using twist-lock stepless quick connectors to the inflow cuffs and outflow grafts. Left-right flow balance is achieved with an atrial hydraulic shunt placed between the left cuff and inflow valve. Animal studies show that the TAH fits very well in Long Horn calves weighing 90 to 100 kg and can provide cardiac output in excess of 10 L/min. A cadaver (85 kg) study showed the TAH fits within the pericardial region.

Adult↗
PubMedDate not supplied

Life testing of implantable batteries for a total artificial heart.

Although lithium cells may promise to be ideal as a rechargeable internal battery for a TAH, NiCd cells remain the most easily accessible off the shelf energy source. Twelve 1.2 A.hr prismatic NiCd (Sanyo, San Diego, CA) cells in series are being tested under the load condition of our TAH. The load consisted of a 1.5 A DC current with 1 A pulses of 40 msec duration at 3.33 Hz (100 bpm), a condition that can generate up to 8 L/min of cardiac output at physiologic pressures. Cells were tested at 37 degrees C. Cell voltages and temperatures were monitored. Testing was accelerated to five charge/discharge cycles per day. Discharge was terminated when any one cell dropped below 1.1 V. Charging (C/4) was continued until the battery voltage indicated a change in slope. Cell temperatures remained below 42 degrees C throughout the charge/discharge cycle. The battery pack settled to a nearly constant capacity of over 25 min after 10 cycles and has accumulated more than 1,000 cycles. Voltage differences among cells were small (SD < 25 mV), indicating consistency among cells. NiCd cells can serve as a reliable interim for TAH internal battery application.

Cadmium↗